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Background: CD4 T lymphocyte activation requires T cell receptor (TCR) engagement by peptide/MHC (major
histocompatibility complex) (pMHC). The TCR complementarity-determining region 3 (CDR3) contains variable α and β
loops critical for pMHC recognition. During any immune response, tuning of TCR usage through progressive clonal
selection occurs. Th1 and Th2 cells operate at different avidities for activation and display distinct transcriptional
programs, although polarization may be plastic, influenced by pathogens and cytokines. We therefore hypothesized
that CDR3αβ sequence features may intrinsically influence CD4 phenotype during progression of a response.
Results: We show that CD4 polarization involves distinct CDR3α usage: Th1 and Th17 cells favored short TCR CDR3α
sequences of 12 and 11 amino acids, respectively, while Th2 cells favored elongated CDR3α loops of 14 amino acids,
with lower predicted affinity. The dominant Th2- and Th1-derived TCRα sequences with14 amino acid CDR3 loops and
12 amino acid CDR3 loops, respectively, were expressed in TCR transgenics. The functional impact of these TCRα
transgenes was assessed after in vivo priming with a peptide/adjuvant. The short, Th1-derived receptor transgenic T cell
lines made IFNγ, but not IL-4, 5 or 13, while the elongated, Th2-derived receptor transgenic T cell lines made little or
no IFNγ, but increased IL-4, 5 and 13 with progressive re-stimulations, mirrored by GATA-3 up-regulation. T cells from
primed Th2 TCRα transgenics selected dominant TCR Vβ expansions, allowing us to generate TCRαβ transgenics
carrying the favored, Th2-derived receptor heterodimer. Primed T cells from TCRαβ transgenics made little or no IL-17
or IFNγ, but favored IL-9 after priming with Complete Freund’s adjuvant and IL-4, 5, 9, 10 and 13 after priming with
incomplete Freund’s. In tetramer-binding studies, this transgenic receptor showed low binding avidity for pMHC and
polarized T cell lines show TCR avidity for Th17 > Th1 > Th2. While transgenic expression of a Th2-derived, ‘elongated’
TCR-CDR3α and the TCRαβ pair, clearly generated a program shifted away from Th1 immunity and with low binding
avidity, cytokine-skewing could be over-ridden by altering peptide challenge dose.
Conclusion: We propose that selection from responding clones with distinctive TCRs on the basis of functional avidity
can direct a preference away from Th1 effector responses, favoring Th2 cytokines.
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In CD4 immunity, different contexts of antigen recogni-
tion, whether in the ‘natural setting’ of disease or the ex-
perimental setting of antigen-priming adjuvant regimens,
favor the preferential development of effector populations
that belong primarily to Th1, Th2 or Th17 subsets [1,2].
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unless otherwise stated.Th2 immunity, while influenza infection induces a Th1
profile [3,4]. There are several mechanisms driving CD4 T
cells into these alternate differentiation fates, including
the local cytokine milieu. This partly reflects the experi-
mental designs most accessible for reductionist models
(that is, adding recombinant cytokines to purified, naïve
cells to track polarization). However, it has relevance ex-
tending to the mechanisms involved in natural infection.
Dendritic cell (DC) programming through IL-12 or IL-18
leading to Th1-polarization is commonly modeled by
Toll-like receptor (TLR) agonism with bacterial products,
the prototypic example being TLR agonism by bacterialal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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environment is less clear. IL-10 and IL-4 are candidates
for the promotion of an innate Th2-priming environment.
However, IL-10 or IL-4 knockout DC can drive Th2 re-
sponses [6]. Clues as to the supply of a pro-Th2 DC pro-
gram have come from looking at Th2-associated pathogen
responses. Schistosome egg antigen (SEA), which induces
a robust Th2 program in DC, capable even of overriding
bacterial Th1 signals [7], depends on a relatively non-
activated transcription profile in the DC, somewhat rem-
iniscent of a tolerogenic profile [8]. This is in keeping with
the view that activation of Th2 cells may encompass re-
duced T cell receptor (TCR) avidity and/or co-stimulation
and altered signaling, synapse formation and off-rates.
Several lines of evidence suggest that Th2 activation has
different avidity requirements for Th1 activation. A basic
precept is that the TCR reads different potencies of ac-
tivation to initiate different effector outcomes with the
‘strength of stimulation’ required for a Th1 response grea-
ter than for a Th2 response [9]. Furthermore, more sus-
tained engagement of the TCR by pMHC is required to
polarize TCR transgenic lymphocytes into a Th2 program
[10]. The serial triggering model of T-cell activation offers
an explanation for these observations; since any given
pMHC complex must activate several receptors for cell
triggering, the affinity of the interaction must be low and/
or the off-rate fast to enable disengagement to occur and
the more sustained the necessary interaction, the greater
this will be the case [11]. There are many studies on the
relative dose of antigen required for a Th1 or Th2
response; a common observation is that Th1 responses
require relatively high concentrations, and Th2 responses
much lower [12]. Possible mechanisms for a relationship
between antigen dose and T cell polarization may be both
through a direct effect on differential CD3 signaling
[13] and through the ability to modulate expression of
co-stimulatory molecules expressed by CD4 cells; high
antigen dose can favor Th1 development through dose-
dependent up-regulation of CD40L [14]. Indeed, it has
been argued that Ca2+ signaling may be reduced in Th2
response and that the threshold interaction necessary
for inducing Ca2+ signaling may not be reached by Th2
cells [15].
In several models, pMHC complexes showing reduced
affinity interactions with TCR are associated with pre-
ferential skewing to a Th2 response. T cells specific for
proteolipoprotein (PLP) 131-159 and selected under Th2-
favoring conditions show a shift in peptide-TCR primary
contact residues compared with Th1 clones [16].
While avidity maturation on a per-cell basis is a prop-
erty of the B cell and not the T cell repertoire, T cell clonal
selection leads to the progressive appearance of selective
TCR usage [17-19]. For example, the repertoire of TCR re-
sponse to sperm whale myoglobulin 110-124 in adjuvantis initially diverse, then progressively losing lower affinity
clones and resulting in an oligoclonal population of TCRβ
receptors of intermediate affinity [18]. Similarly, pigeon
cytochrome c peptide specific TCRβ chains show strong
selection for CDR3 length and residues characteristic of
antigen binding, compatible with progressive clonal ma-
turation and the suggestion of population-level affinity
maturation [19]. Repertoire maturation in development of
the CD8 response to Listeria involves narrowing of the
TCR repertoire, associated with increased affinity [17].
Knowing that development of a response involves
selective fine-tuning from available receptors and that
avidity requirements differ for activation of different Th
subsets, it would be expected that they might selectively
expand different TCR repertoires. We previously showed
that selection of favored TCRs from the peptide-specific
pool differs under Th1 or Th2 conditions [20]. When an
initial, mixed pool of primed cells was divided into Th1 or
Th2 polarized cultures, different TCR sequences were
preferentially selected under the two conditions. Across
different pMHC combinations, there was no clear pattern
or homogeneity evident in the selection for TCRβ usage,
but Th2 conditions preferentially selected elongated
CDR3α sequences. The example of the response to PLP
56-70/H-2Ag7 was studied in detail. Screening of polarized
Th line libraries suggested that while Th2 cultures favored
these elongated CDR3α loops but also encompassed re-
ceptors with shorter loops, the long loops could never be
found in Th1 cultures. Molecular modeling offered a po-
tential explanation, predicting a bulky, obstructive inter-
action of reduced affinity for the elongated Th2 receptors.
Thus, contrary to experiments with the DO11.10 TCR
transgenic mouse, whereby a Th1-derived TCR can be
skewed to mediate either Th1 or Th2 effector functions
[21], in a physiological polarizing environment, receptor
features may be preferentially selected so as to skew the
future memory response for an appropriate cytokine pro-
file [22]. While it had been envisaged that the cytokine
program was faithfully transmitted to progeny cells by
chromatin remodeling, polarization is now perceived as a
plastic event [2,23-28]. In this context, there may be evo-
lutionary advantage in building information on the appro-
priate response into the TCR itself, so that the response
cannot be diverted to a pathogen-inappropriate response
by the local inflammatory environment.
We here investigate this hypothesis by generating TCR
transgenics carrying an elongated CDR3, Th2-derived
TCRα chain. We show that cells carrying this receptor,
particularly when paired with the appropriate TCRβ
partner, facilitate cytokine skewing away from a Th1 pro-
gram. This is the first time to our knowledge that a
causal link between TCR repertoire maturation and Th
effector polarization has been shown. The findings sug-
gest that the program for recall of a context-appropriate
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genetic changes, but also in the choice of dominant
TCRs themselves.
Results
TCR usage and co-stimulatory molecule expression in
polarized CD4 T cell lines
We previously described the relatively homogeneous
TCRα usage associated with a polarized Th2 response to
PLP 56 to 70 [20,22]. A noteworthy feature of this TCR
usage was the choice of CDR3α loops that were elongated,
an observation extended across several different pMHC
combinations, suggesting that the Th2 cytokine environ-
ment had influenced preferential utilization of TCRs with
these structural features. In order to establish the impact
on cytokine polarization of Th2-derived receptors with
these features, TCRα chain transgenic lines expressing a
representative, elongated CDR3α receptor were generated.
In order to select such a TCR sequence, we sequenced
TCRα and β chains from polarized Th lines specific for
this pMHC combination (H2-Ag7/PLP 56 to 70). Primed
lymph node cells (LNC) from mice primed with peptide
in Complete Freund’s adjuvant (CFA) were split into cul-
tures stimulated with antigen in vitro under polarizing
Th1, Th2 or Th17 conditions. To generate Th1 lines, cells
were cultured in medium containing IL-2, IL-12 and anti-
IL-4. To generate Th2 lines, cells were cultured in me-
dium containing IL-2, IL-4 and anti-IFNγ. For Th17 lines,
cells were initially cultured in anti-IFNγ, anti-IL-4, IL-6
and TGFβ and expanded in medium containing IL-2 and
IL-23. Each set of conditions yielded a repertoire of TCRs
with reproducibly distinct features (Tables 1, 2, 3). In
each case, the distinctive CDR3s were a characteristic of
the TCRα and not the TCRβ repertoire. Under Th1
conditions, cultures predominantly favored a Vα15Jα10
(TRAV10D TRAJ58) receptor with a 12 amino acid
CDR3α, AASREGTGSKLS. We never found this receptor
or ones similar to it in cultures derived from the same
LNC pool but polarized under Th2 or Th17 conditions.
Cells cultured under Th2 polarizing conditions favored
very different TCRα usage, a quarter of the sequences com-
prising a Vα9Jα42 (TRAV17 TRAJ50) receptor with an
elongated, 14-amino acid CDR3α loop, ALEGIASSSFSKLV.
This was not accompanied by any overt selection for dom-
inant TCRβ chains. Interestingly, cells cultured under Th17
polarizing conditions were also distinctive, a large pro-
portion of sequences (44%) being Vα11Jα21 (TRAV4D-3
TRAJ27) comprising a short, 11 amino acid CDR3α loop
(AAANTNTGKLT). Again, there was no preferred, ex-
panded TCRβ chain. The findings suggested selection
from the available pool primarily on the basis of TCRα se-
quence and permissible pairing of dominant TCRα chains
with multiple possible β chain partners. The Th17 cells
were similar to Th1-polarized cultures in being limited toshort CDR3α loops. There was no significant difference in
TCRβ chain CDR3 length seen in Th1 (12.3 ± 0.2), Th2
(12.3 ± 0.2) and Th17 (12.7 ± 0.2) TCR sequences. How-
ever, TCRα chain CDR3 lengths were significantly longer
in Th2 (12.2 ± 0.2) than in Th1 (11.4 ± 0.1) and Th17
(11.1 ± 0.1) TCR sequences (P <0.0009).
When assayed for release of IFNγ, IL-4, IL-5, IL-9, IL-13,
IL-10 and IL-17, each of the polarized lines showed the ex-
pected profiles (Figure 1A). A caveat here is that, in line
with observations from others using in vitro and in vivo
models, T cells within Th17 cultures could flip relatively
easily into co-expression of IL-17 and IFNγ [24-27] or
single expression of IFNγ, (Additional file 1) particularly if
derived from an ex-vivo inflammatory environment.
In line with the idea that selection from the initial pool
under Th polarizing conditions acts through selection of
clones with differing avidities, Th1 and Th2 lines devel-
oped with markedly differing profiles of co-stimulatory
molecule expression (Figure 1B-F). Th1 lines show greater
expression of CD40L, in line with the idea that CD40L-
blockade preferentially blocks Th1 responses (Figure 1E)
[14]. Expression of OX40, Intercellular adhesion mole-
cule-1 (ICAM-1) and CD5 were also greater on Th1 lines
(Figure 1B-D). Conversely, Th2 inducible T-cell co-stimu-
lator (ICOS) expression was greater, as predicted by the
finding that ICOS stimulation preferentially triggers Th2
cytokines (Figure 1F) [28]. The CD5 expression differences
are reminiscent of observations in a recent paper by
Mandl and colleagues, who showed that TCR transgenic
CD5hi clones accounted for high tetramer binding [29].
Generation of TCRVα chain transgenics
We expressed the immunodominant selected TCRα se-
quence (Vα9Jα42 (TRAV17 TRAJ50) receptor with an
elongated, 14-amino acid CDR3α loop, ALEGIASSSFSKLV)
in the pTα expression cassette, and made two independ-
ent transgenic founder lines expressing the dominant
Th2-derived TCRα chain with an elongated CDR3 region
(line 20 and line 34). We expressed the immunodominant
selected TCRα sequence (Vα15Jα10 (TRAV10D TRAJ58)
receptor with a 12-amino acid CDR3α, AASREGTGSKLS)
in the pTα expression cassette, and made one transgenic
founder line with the dominant Th1-derived TCRα chain
with a shorter CDR3 region (line 30). All the transgenic
lines were then backcrossed onto the original non-obese
diabetic, H2-E transgenic (NOD.E) background in which
the T cells had been characterized (Figure 2A, B).
Transgenic expression of TCRVα chain with an elongated
CDR3 does not favor Th1 responses in primed cells
With respect to TCR selection in Th2 T cell lines, the
absence of any dominant TCRβ chain in cultures led us
to hypothesize that transgenic expression of the TCRα
chain with an elongated CDR3 region alone might be
Table 1 TCR α and β chain repertoires of a Th1 polarized T cell line
CDR3 region CDR3 length %
TCR alpha EDSAIYFC AASREGTGSKLS FGKG 12 34
SDSAKYFC ALEGRGGRALI FGTG 11 20
EDSGTYFC AALPGTGSNRLT FGKG 12 18
GDSAMYFC AAKNSGTYQR FGTG 10 8
GDSAIYFC SASMTNNNNRIF FGDG 12 6
EDSGTYFC AADSNYQLI WGSG 9 4
EDSGTYFC AAETNSAGNKLT FGIG 12 2
EDSGTYFC AADSNHQLI FGSG 9 2
EDSGTYFC AAEAANYNVLY FGSG 11 2
EDSAIYFC AASKPNNRIF FGDG 10 2
SDSAVYFC ALSALGTGNYKYV FGAG 13 2
TCR beta DDSATYFC ASSQGPLSNERLF FGHG 13 22
NEMAVLFC ASSRSGDQDTQY FGPG 12 18
EDSAVYLC ASSRDWGDTQY FGPG 11 14
DDSATYFC ASSQEMQGQDTQY FGPG 13 6
EDSAVYLC ASSPWGVQDTQY FGPG 12 4
QDSAVYLC ASSLAGQGARSQNTLY FGAG 16 4
SQTSLYFC ASSPGSNERLF FGHG 11 4
KDSAVYLC ASSLVGAEQF FGPG 10 4
DDSATYFC ASSKAGTGEDTQY FGPG 13 2
DDSATYFC ASSQQGDQDTQY FGPG 12 2
DDSATYFC ASSQEGTGVQDTQY FGPG 14 2
DDSATYFC ASSQEGTGGDEQY FGPG 13 2
DDSATYFC ASSQEGLSSYEQY FGPG 13 2
DDSATYFC ASSQEGLGNYEQY FGPG 13 2
DDSATYFC ASSQEMQGDQDTQY FGPG 14 2
QDSAVYLC ASSNQNYAEQF FGPG 11 2
QDSAVYLC ASSSRDWGDEQY FGPG 12 2
EDSAVYFC ASSQAGTDTQY FGPG 11 2
EDSAVYFC ASSSPGGSYEQY FGPG 12 2
SQTSVYFC ASGDSQGANQAPL FGEG 13 2
T cell lines were maintained in culture for one round of re-stimulation under highly polarizing conditions before taking RNA for TCR sequence analysis. TCRα and β chain
repertoire analysis of an H2-Ag7/PLP 56-70 specific Th1, Th2 and Th17 cell lines shows expansion of distinct, dominant TCRα chains in the absence of a dominant β chain.
The frequency (%) of each unique TCR sequence identified is shown. CDR3 length is defined as the number of amino acids between the invariant C residue and the
F/W-G-X-G motif. TCRα and TCRβ CDR3 region lengths are shown in each table. Data are representative of 50 TCRα and 50 TCRβ sequences for each T cell line. The
mean CDR3 length for the TCRα chain is 12.2 ± 0.2 (SE) for Th2 cultures, 11.4 ± 0.1 (SE) for Th1 cultures, and 11.1 ± 0.1 (SE) for Th17 cultures.
The most dominant TCR alpha sequence is shown in bold.
Mean CDR3α length 11.42 + 0.13 (SE) (n = 50).
Mean CDR3β length 12.30 + 0.17 (SE) (n = 50).
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response.
We initially assessed the functional impact of the elon-
gated TCRα chain on CD4+ T cell responses by immuniz-
ing mice to look both at initial recall responses and
subsequently after a second antigen boost in vivo (Figure 3).
The nature of ex-vivo cytokine responses is heavily in-
fluenced by the adjuvants used for priming, with CFA
giving strong Th1 polarization through the effect of M.tuberculosis on MyD88-dependent signaling [30]. We,
therefore, assessed whether this TCR could confer pro-
pensity to develop a Th2 program in the face of a Th1-
skewing, CFA priming regimen. Mice were immunized on
Day 0 and Day 28 with PLP 56 to 70 in CFA and in-
complete Freund’s adjuvant (IFA), respectively, and T cell
responses sampled at days 10, 28 and 32. At each time-
point, T cell responses of TCRα chain transgenics were
similar to littermate controls as judged by proliferation
Table 2 TCRα and β chain repertoires of a Th2 polarized T cell line
CDR3 region CDR3 length %
TCR alpha SDSAKYFC ALEGIASSSFSKLV FGQG 14 24
GDSAAYFC AVRGTNAYKVI FGKG 11 16
SDSALYYC ALSDANNYAQGLT FGLG 13 14
GDSAAYFC AAGDTNTGKLT FGDG 11 10
EDSAIYFC AASRGNMGYKLT FGTG 12 8
GDSAAYFC AALNTNTGELT FGDG 11 6
SDSAVYYC ALVRDTGYQNFY FGKG 12 4
SDSAVYYC ALGEDTNAYKVI FGKG 12 4
SDSAVYYC ALGFQGGRALI FGTG 11 4
GDSAMYFC AAPPMNYNQGKLI FGOG 13 4
TDSGTYFC AMERODNYAOGLT FGLG 13 2
EDSGTYFC AADNRIF FGDG 31 2
SDSAVYYC ALGDREGGRALI FGTG 15 2
TCR beta QDSAVYLC ASSFQTGGAETLY FGSG 13 6
NEMAVFLC ASSSPTGGWNAEQF FGPG 14 6
EDSAVYLC ASSNYAEQF FGPG 9 6
DDSATYFC ASSLGTGDAEQF FGPG 12 6
DDSATYFC ASSLRDNGDTQY FGPG 12 6
DDSATYFC ASSOEAGGVDTQY FGKG 13 4
NEMAVFLC ASSPRTTSGNTLY FGEG 13 4
NEMAVFLC ASSPPTGSPNERLF FGHG 14 4
EDRGLYLC GARDLWGGKNTLY FGAG 13 4
DDSATYFC ASSQEGLDSYEQY FGPG 13 4
NEMAVFLC ASSIEDSGTEVF FGKG 12 4
QDSAVYLC ASSLRGHTEVF FGKG 11 2
ODSAVYLC ASSVRDWGDTQY FGPG 12 2
QDSAVYLC ASSLRNTEVF FGKG 10 2
DDSATYFC ASSQEGWGPYEQY FGPG 13 2
DDSATYFC ASSQGLGNYAEQF FGPG 13 2
DDSATYFC ASSQEGTGGYAEQF FGPG 14 2
DDSATYFC ASSQDGTGGYAEQF FGPG 14 2
DDSATYFC ASSQGIYEQY FGPG 10 2
DDSATYFC ASSPANSDYT FGSG 10 2
DDSATYFC ASSQDGTIODTQY FGPG 13 2
DDSATYFC ASSPDWDTTGQLY FGEG 13 2
DDSATYFC ASSQDRSSSAETLY FGSG 14 2
DDSATYFC ASSQEGTGGKEQY FGPG 13 2
NEMAVFLC ASSSPTGGWNAWQF FGPG 14 2
EDSAVYLC ASSPRGLYAEQF FGPG 12 2
EDSAVYLC ASSRDWGSEQY FGPG 11 2
EDSAVYLC ASSPDWGDEQY FGPG 11 2
SQTAVYFC ASSGRTTANTEVF FGKG 13 2
SQGRTLYC TCSADGSYEQY FGPG 11 2
EYSAMYLC ASSSGGFAETLY FGSG 12 2
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Table 2 TCRα and β chain repertoires of a Th2 polarized T cell line (Continued)
EYSAMYLC ASRDWGETLY FGSG 10 2
SHSGFYLC AWSLWSGVANERLF FGHG 14 2
SQTSLYFC ASSDFSTEVF FGKG 10 2
The most dominant TCR alpha sequence is shown in bold.
Mean CDR3α length 12.24 ± 0.20 (SE) (n = 49).
Mean CDR3β length 12.25 ± 0.20 (SE) (n = 51).
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controls generated a strong IFNγ response, this was absent
after the initial recall in the TCRα transgenics at Day 28
(P <0.05) (Figure 3B). This suggested that use of this recep-
tor was less effective at maintaining IFNγ transcription.
When mice were boosted, we observed an IFNγ response
in littermates but not in TCRα transgenics (Figure 3C).
T cells from the TCRα chain transgenics were harvested
at Day 32, cultured with peptide for 48 h and CDR3 ana-
lysis of the CD4+CD69+ (n = 50) and CD4+CD69− (n = 48)
cells was carried out. The lack of an IFNγ response in
TCRα transgenics after boosting correlated with selection
of a single shared Vβ2 partner chain, as demonstrated by
TCR sequencing and by spectratyping using V gene
specific primers (Figure 3D, E). All the CD4+CD69+ cells
expressed the same TCRβ chain, TRBV2 TRBJ2-5 with
an elongated 13-amino acid CDR3 region ASSQAGT-
GEDTQY. Thus, the defective IFNγ recall response was
associated with the clonal expansion of a population of
cells expressing a single TRBV2 TRBJ2-5 chain with an
elongated CDR3.
Cytokine polarization evolves in cultured cell lines in line
with favored TCRαβ selection
In order to look in more detail at the relationship between
progressive polarization and focusing of the TCR reper-
toire, we set out to look at polarization and TCRβ se-
lection during progressive re-stimulation of T cell lines
in vitro. This was done in the absence of exogenous pola-
rizing factors in the medium. This allowed us to further
explore the possibility that, with progressive re-stimulation
and selection, there may be increasing focus on particular
TCR pairs, leading to impaired Th1 responses and gradual
promotion of Th2 responses. Primed draining LNC were
used to establish T cell lines in vitro. Elongated CDR3
TCRα chain transgenic lines 20 and 34, short CDR3 TCRα
chain transgenic line 30 and transgene negative littermate
controls were primed with peptide in CFA and, 10 days
later, LNC were harvested and T cell lines established. Line
20 and line 34 TCRα transgenic cells rapidly selected do-
minant TCRβ chain expansions (Figure 4A). By the fourth
re-stimulation, over half of the TCRβ repertoires for the
TCRVα transgenic lines comprised a single Vβ chain
(although differing between the founder lines: VRBV31
TRBJ2-3; CAWSLGGGAETLYF in the case of line 20 and
TRBV13-1 TRBJ2-7; CASSDTGGAQSSYEQY in line 34)and by the sixth re-stimulation, the TCRVβ repertoire was
composed almost exclusively of this Vβ chain. These stu-
dies, along with the studies shown above in Figure 3, argue
that several different TCRβ chains can pair with the elon-
gated TCRα chain to yield the desired pMHC specificity
and that in a given mouse or T cell line, one of several pos-
sible sequences may acquire clonal dominance. This selec-
tion of TCRβ chains in the context of pMHC activation
was confirmed by spectratyping (Figure 4B). As early as
the second re-stimulation, CD4 T cell lines from line 20
TCRα transgenics show constrained spectra, with a signifi-
cant contraction of the TCRVβ chain repertoire for several
Vβ gene families while spectra from littermate control T
cell lines show TCRVβ diversity (Figure 4B).
We then looked at this TCR focusing during evolution
of a given T cell line in relation to skewing of cytokine
production. At the same time as making cDNA at each
re-stimulation for TCR sequence analysis and spectraty-
ping, cytokine production was analyzed by ELISA and
RNA used for real-time analysis of subset-specific tran-
scription factors. With progressive re-stimulations in vitro,
the reciprocal nature of Th1 and Th2 polarization in
littermate controls and TCRα transgenic lines with the
shorter compared to those with elongated CDR3 regions
is seen. TCRα transgenics with the elongated CDR3 region
(line 20) make little or no IFNγ, but, after a lag of one re-
stimulation, make large amounts of IL-4, IL-5 and IL-13
(Figure 4C). TCRα transgenic lines with the shorter CDR3
region (line 30) and non-transgenic controls make IFNγ,
but no IL-4, IL-5 and IL-13. In line with this, GATA-3
transcription is progressively up-regulated in TCRα elon-
gated CDR3 transgenic cultures compared with littermate
controls (Figure 4D).
There is no bias of the TCRVβ chain repertoire in
naïve TCRVα chain transgenic splenocytes at Day 0
(Additional file 2A), or in a primary response in draining
lymph nodes at Day 10 post-immunization as demon-
strated by spectratype analysis (Additional file 2B).
Generation of TCRαβ transgenics
The likely interpretation of the simultaneous appearance
of dominant TCRβ chain sequences in the TCRα chain
transgenic lines, adoption of a spontaneous Th2 pheno-
type and impaired Th1 program, was thus that features
of this preferred TCRαβ pair were incompatible with ef-
fective maintenance of Th1 activation and, therefore,
Table 3 TCRα and β chain repertoires ot a Th17 polarized
T cell line
CDR3 region CDR3 length %
TCR alpha EDSGTYFC AAANTNTGKLT FGDG 11 44
EDSGTYFC AAEDNNNNAPR FGAG 11 16
EDSGTYFC AAMNYNQGKLI FGQG 11 6
EDSGTYFC AAVDYNQGKLI FGQG 11 4
TDSGTYLC AMDMNNNNAPR FGAG 11 4
EDSGTYFC AAEAPSSGQKLV FGQG 12 4
GDSAVYFC AVSVDNYAQGLT FGLG 12 4
EDSGTYFC AAMNTNTGKLT FGDG 11 2
EDSGTYFC AANNYNQGKLI FGQG 11 2
EDSGTYFC AAEGNSGTYQR FGTG 11 2
EDSGTYFC AAEDSGGNYKPT FGKG 12 2
EDSGTYFC AAYNYAQGLT FGLG 10 2
EDSGTYFC AAEADTNAYKVI FGKG 12 2
EDSGTYFC AAGPHNNNAPR FGAG 11 2
TDSGTYLC AMER6TNTGKIJT FGDG 12 2
SDSAVTPC AARSDTNAYKVI FGKG 12 2
TCR beta EDSAVYLC ASSSTGGAHYAEQF FGPG 14 8
QDSAVYLC ASSLVGQGDTQY FGPG 12 6
DDSATYFC ASSQDQISQNTLY FGAG 13 6
DDSATYFC ASSQDLGTSNERLF FGHG 14 6
SQTSVYFC ASGDSAGGNSPLY FAAG 13 4
SQTSVYFC ASAWGENTLY FGAG 10 4
ODSAVYLC ASSLDTGYTEVF FGKG 12 2
QDSAVYLC ASSLGQGTEVF FGKG 11 2
QDSAVYLC ASSLAPGQGDERLF FGHG 14 2
QDSAVYLC ASSLDQTNERLF FGHG 12 2
ODSAVYLC ASSLAGANTGQLY FGEG 13 2
QDSAVYLC ASSLDAGQNYAEQF FGPG 14 2
QDSAVYLC ASSPPDTYEQY FGPG 11 2
ODSAVYLC ASSPQGYQDTQY FGPG 12 2
ODSAVYLC ASSLDWGEGNTLGL FGAG 14 2
SQTSVYPC ASGDGTGGRDE0P FGPG 13 2
SQTSVYFC ASG6GTASNERLF FGHG 13 2
S0TSVYFC ASGETANTEV FGKG 10 2
SQTSVYPC ASSDAGTGRDTEVF FGKG 14 2
SQTSVYFC ASSDAAGGFIAEQF FGPG 14 2
SQTSVYFC ASSDAGVTGQLY FGEG 12 2
SQTSVYFC ASSDGQNTLY FGAG 10 2
SQTSVYFC AGSGDWGDEQY FGPG 11 2
SQTSVYFC ASSAGQQDTQY FGPG 11 2
SQTSVYFC ASSDAGTGRDTEVF FGKG 14 2
SQTSVYFC ASSDEGTKPDTEVF FGKG 14 2
SQTSVYFC ASSDDRVNERLF FGHG 12 2
Table 3 TCRα and β chain repertoires ot a Th17 polarized
T cell line (Continued)
SQTSVYFC ASSPSGTGSYEQY FGPG 13 2
SQTSVYFC ASSDDRVNERLF FGHG 12 2
DDSATYFC ASSQEGTGGDEQY FGPG 13 2
DDSATYPC ASSQEKGQGYAEQF FGPG 14 2
NQTSVYFC ASSSPFNSYNSPLY FAAG 14 2
NQTSVYFC ASSLRTGGGGTEVF FGKG 14 2
SHSGFYLC AWSHNRGNSDYT FGSG 12 2
EYSAMYLC ASSGPSTGRDTEVF FGKG 14 2
EYSAMYLC ASSRGDWGNEQY FGPG 12 2
NEMAVFLC ASSMGTYAEQF FGPG 11 2
EDSAVYLC ASSSLGGRNYAEQF FGPG 14 2
EDSAVYLC ASSLGLGAETLY FGSG 12 2
The most dominant TCR alpha sequence is shown in bold.
Mean CDR3α length 11.14 ± 0.06 (SE) (n = 50).
Mean CDR3β length 12.70 ± 0.18 (SE) (n = 50).
Reynolds et al. BMC Biology 2014, 12:32 Page 7 of 24
http://www.biomedcentral.com/1741-7007/12/32favored emergence of a Th2 response. We therefore
expressed one of the immunodominant, selected TCRβ
sequences (TRBV31 TRBJ2-3; CAWSLGGGAETLYF)
in the pTβ expression cassette (Figure 2C), generated
TCRβ transgenics, and crossed these to line 20 TCRα
transgenics on the same NOD.E background.
TCRαβ transgene impacts on ex-vivo T cell phenotype
To assess the functional impact of the TCRαβ on primary
ex-vivo T cell responses to peptide, TCRαβ transgenics
and littermate controls were primed with peptide/CFA,
again supplying a maximal Th1-skewing environment. At
Day 10, T cell responses were analyzed ex-vivo and T cell
lines established. While TCRαβ transgenics, as would be
expected, show enhanced T cell proliferation responses to
peptide, IFNγ and IL-17 responses were absent, and they
made substantial amounts of IL-9 (Figure 5A). As before,
immediately ex-vivo we could detect no IL-4, IL-5 or IL13
(data not shown). The absent production of IFNγ and
IL-17 and enhanced production of IL-9 observed in the
TCRαβ transgenic line was seen in the context of priming
with the Th1 promoting adjuvant CFA making this result
all the more striking. IL-10 production was not signifi-
cantly different between the groups.
The phenotype of the TCRαβ transgenic lines was fur-
ther confirmed by real time PCR for IFNγ, GATA-3 and
RORγt. The TCRαβ transgenic lines expressed high levels
of GATA-3 (P <0.004; unpaired t-test) and low levels of
IFNγ and RORγt relative to the littermate controls in
keeping with a Th2 phenotype (Figure 5B). Furthermore,
GATA-3 expression increased with successive re-stimula-
tions, while RORγt expression decreased in keeping with
the reduction in IL-17 production (Figure 5C). The level
of T-bet transcription, however, showed no obvious
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http://www.biomedcentral.com/1741-7007/12/32pattern through re-stimulations of the TCR transgenic or
WT lines (Additional file 3). This is in line with an in-
creasingly complex model for T-bet in the Th1 program:
in several models, Th2 polarization occurs in the face of
T-bet transcription [31,32].
Because our investigations had used CFA priming, it
was important to gauge the effect of immunizing TCRαβ
double transgenic, TCRα chain single transgenic and lit-
termate control transgenics with peptide in IFA lacking
Th1-skewing killed mycobacteria (with the caveat that this
is a less effective way of priming T cell responses). At Day
10, LNC were harvested and 3H-thymidine incorporation
and cytokine production determined ex-vivo. The results
are in line with the larger pMHC-specific T cell response
in the TCRαβ transgenics, but confirm the Th2 bias:
TCRαβ transgenic cells respond strongly to peptide ma-
king IL-4, IL-5, IL-9, IL-10 and IL-13, but no IFNγ or
IL-17 (Figure 5D). TCRα chain transgenics, and littermate
controls made IL-5 and small amounts of IL-10 only
(Figure 5D). This is in keeping with the TCRαβ receptor
supporting a Th2 phenotype.
Addressing alternative hypotheses for cytokine-skewing
in the TCR transgenics
The TCRαβ transgenic lines make more IL-2 than
littermate controls, indicating T cell survival potential
(Figure 5A). The high IL-2 response in the TCRαβ
transgenic line, taken together with the high IL-9 and
IL-10 response, implies that there is no global failure of
T cell activation/survival per se, but merely a cytokine-
deviated response. This appears to argue against a possible
alternate hypothesis, that increased precursor number
may have caused greater competition for IFNγ signals and
decreased T cell fitness and/or memory [33-35]. To fur-
ther address this issue, we immunized TCRαβ transgenics
and littermate controls on Day 0 and Day 28 with PLP 56
to 70 in CFA and IFA, respectively, and looked at markers
of cell activation and cell survival by real-time PCR and
fluorescence activated cell sorter (FACS). Real-time PCR
analysis of B-cell lymphoma-extra large (Bclxl) expression
gave no indication of an enhanced propensity to apoptosis
(Additional file 4A). Anti-apoptotic proteins, such as
Bclxl, are involved in protecting mitochondrial integrity,
for example, in the context of limiting growth factors [36].
Bclxl is induced on T cell activation and enhanced by co-
stimulation of CD28 [37], and it is generally considered
that over-expression of B-cell lymphoma 2 (Bcl-2) or Bclxl
in T cells prevents death by neglect [33,38,39]. Fur-
thermore, data from Gett and colleagues indicate that
induction of Bclxl on sustained activation depends on
stimulation strength and is associated with resistance to
apoptosis, Bclxl increase being greatest in T cells that had
received prolonged stimulation. If TCR transgenic cells
were incapable of fully functional stimulation and destinedfor some form of sub-optimal stimulation or death by neg-
lect, one would predict diminished activation of Bclxl in
the transgenic response. In fact, we found no difference in
Bclxl expression. Taken together with the other evidence
shown here, including the strong IL-2 response on activa-
tion, we interpret the findings to mean that there is no
deficit in activation of the response through the transgenic
receptor, but rather, deviation of the transcriptional re-
sponse to an altered cytokine profile. Furthermore, pheno-
typic analysis of the primed lymphoid populations at Day
28 showed no difference in activation/fitness as indicated
by staining for CD127 (Additional file 4B). It has been
shown by Whitmire and colleagues in a transgenic lym-
phochoriomeningitis virus (LCMV) response cell transfer
model that only when the number of transferred T cell
precursors was low did they generate fully functional
memory cells that were CD127/IL-7R (high), with full ca-
pacity to produce cytokine and proliferate. Testing there-
fore whether it was possible that an excess of responder
cells here correlated with a response phenotype that was
in some way impaired, we analyzed T cell expression of
CD127, and found that transgenic cells had enhanced, not
reduced expression. Taken together with the other evi-
dence presented here, this makes it unlikely that this was
a model of sub-optimal activation. Furthermore, expres-
sion of CD62L was similar in the transgenic and littermate
responder populations (Additional file 4C). Thus, the indi-
cation from IL-2 release, as well as apoptosis and activa-
tion markers is that the phenotype observed here
constitutes an actively skewed functional preference, ra-
ther than a failure to trigger properly by the transgenic
receptors.
It was hypothetically possible that injection of cog-
nate peptide into a single chain TCRα and TCRαβ
transgenic mice had triggered a cytokine storm due to
the large number of responding T cells, and this had in
turn caused thymic apoptosis leading randomly to a
skewed cytokine outcome in surviving cells. To address
this we conducted additional studies. ‘Cytokine storm’
is a term derived from the systemic response in toxic
or septic shock [40]. Here, an acute, excessive spike of
systemic pro-inflammatory cytokines leads to down-
stream events, often including large-scale lymphocyte
apoptosis. In our studies the positive control stimulus
of SEB led to the predicted spike in systemic pro-
inflammatory cytokines, such as IFNγ and TNFα at 2 h,
but no systemic change in cytokines was detected after
injection of peptide/CFA (Additional file 5A, B). It was
nevertheless possible that even in the absence of a sys-
temic response there may have been some acute,
storm-driven change in thymic populations accounting
in a non-specific way for cytokine skewing. While SEB
had a dramatic effect on overall thymocyte numbers
and CD4/CD8 ratio in littermate control as well as
AB COX40 ICAM-1 D CD5 
E CD40L F ICOS 
Th1 Th2 Th17
0
10,000
20,000
30,000
40,000
50,000
60,000
IL
-
17
 (p
g/
m
l)
Th1 Th2 Th17
0
100
200
300
400
500
600
IL
-
10
 
(p
g/
m
l)
Th1 Th2 Th17
0
250
500
750
1,000
1,250
1,500
1,750
IL
-
13
 (p
g/
m
l)
Th1 Th2 Th17
0
2,000
4,000
6,000
8,000
10,000
12,000
IL
-
9 
(p
g/
m
l)
Th1 Th2 Th17
0
10,000
20,000
30,000
40,000
50,000
60,000
70,000
IL
-
5 
(p
g/
m
l)
Th1 Th2 Th17
0
250
500
750
1,000
IL
-
4 
(p
g/
m
l)
Th1 Th2 Th17
0
50,000
100,000
150,000
200,000
250,000
IF
N-
 
(p
g/
m
l)
Th1 Th2
0
50
100
150
200
250
P < 0.0001
ge
o
m
e
tr
ic
 m
e
a
n
 
flu
o
re
s
c
e
n
c
e
Th1 Th2
0
25
50
75
100
125
150
175
P < 0.0002
ge
o
m
e
tr
ic
 m
e
a
n
 
flu
o
re
s
c
e
n
c
e
Th1 Th2
0
25
50
75
100
125
P < 0.001
ge
o
m
e
tr
ic
 m
e
a
n
 
flu
o
re
s
c
e
n
c
e
Th1 Th2
0
25
50
75
100
125
P < 0.0001
ge
o
m
e
tr
ic
 m
e
a
n
 
flu
o
re
s
c
e
n
c
e
Th1 Th2
0
25
50
75
100
P < 0.03
ge
o
m
e
tr
ic
 m
e
a
n
 
flu
o
re
s
c
e
n
c
e
Figure 1 Th1, Th2 and Th17 polarized T cell lines have distinct cytokine profiles and differ in expression of co-stimulatory molecules.
(A) Th1 (gray bar), Th2 (black bar) and Th17 (white bar) polarized cultures show the expected phenotype (note that, as described by others, Th17
lines can produce IFNγ). Data are shown for five independent Th1 (n = 5), Th2 (n = 5) and Th17 (n = 5) lines. This experiment was repeated on
more than three separate occasions. (B-F) Highly polarized T cell lines derived from the same CFA/peptide immunizations were maintained in
culture for one passage of re-stimulation (10 days) and then analyzed for expression of the indicated co-stimulatory molecules expressed on
CD4-co-stained cells. This experiment was repeated on three separate occasions. Statistically significant differences are indicated (unpaired T test).
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http://www.biomedcentral.com/1741-7007/12/32TCRα and TCRαβ transgenics, no such effect was seen
with cognate peptide (Additional file 5B). None of the
peptide-primed non-transgenic controls showed pre-
ferred TCRβ chains in sorted CD4 SP cells from thy-
mocytes (Additional file 5C). However, in one out of
four of the mice analyzed, TCRβ chains in sorted CD4
SP cells from thymocytes in peptide-primed TCRα
transgenics show preferential selection of a preferred
TCR heterodimer, 44% of TCRs using a common TCRβ
chain (Additional file 5D). On the basis of these experi-
ments, the Occam’s razor hypothesis, that TCRα chains
of differing structures and avidities can influence cyto-
kine program, appears more likely than cytokine prefer-
ence emerging as a stochastic event in the aftermath of
a cytokine storm.T cell lines with TCRαβ receptor have low binding avidity
We previously predicted from molecular modeling stud-
ies that the elongated CDR3 region of the TCRα chain,
when paired with a preferred TCRβ chain, might result
in a lower avidity interaction between the TCR and its
pMHC ligand [20,22]. We therefore started by reapprai-
sing functional avidity in a peptide titration of Th1, Th2
and Th17 polarized, non-transgenic T cell lines cultured
for eight days in polarizing medium and looking at IFNγ,
IL-4 and IL-17 ELISPOTs, respectively. In these short-
term lines, to achieve a response of 100 SFC/106 cells re-
quires about 3 times the peptide concentration in the
Th1 lines compared to Th17, and about 250 times the
peptide concentration in the Th2 lines compared to
Th17 (Figure 6A).
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Figure 2 Schematic diagram illustrating construction of the Th2 derived TCRα chain transgene with an elongated CDR3 region, Th1
TCRα chain transgene with a short CDR3 region, and Th2 TCRβ chain transgene. (A) The Th2-derived TCRα chain transgene with an elongated
CDR3 region, (B) Th1 TCRα chain transgene with a short CDR3 region, and (C) Th2 TCRβ chain transgene showing the recombined V and J gene
segments and the amino acid sequence of the CDR3 regions. Intronic sequences flank the 3′ and 5′ ends of the coding regions and also separate the
leader sequence (LP1) from the main coding region of the V gene. Transgenes were cloned into TCR α or β chain expression vectors that contain TCRα
or β constant regions and endogenous promoter elements, using Xma I/Sac II sites for the TCRα and Xho I/Sac II sites for the TCR β transgene.
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Th1, Th2 and Th17 polarized, non-transgenic T cell lines
cultured for eight days in polarizing medium and pre-
pared from the same initial pool of primed LNC, using
H2-Ag7 tetramers loaded with either PLP56 to 70 or an
irrelevant H2-Ag7-binding peptide (CLIP103 to 117,
PVSKMRMATPLLMQA). At all concentrations of tetra-
mer tested, a significantly greater proportion of Th1 and
Th17 polarized cells bound tetramer compared to Th2 cells
despite equivalent levels of cell surface CD3 (Figure 6B, C).
Similarly, in a peptide titration to examine the functional
avidity of short-term T cell lines from TCRαβ transgenics
relative to littermates, an equivalent number of IL-4 spot-
forming cells in the TCRαβ transgenics require approxi-
mately 50 times the peptide concentration required for
the IFNγ response in littermates (Figure 6D). We then
compared tetramer binding characteristics of T cell lines
derived from the Th2-type TCRαβ transgenic cells, TCRα
chain transgenics with an elongated CDR3 and Th1-type
cells from non-transgenic littermate controls. As tetramer
concentration increased, a higher frequency of Th1 cells
from the control littermate bound tetramer. However, no
tetramer binding was detectable for the TCRαβ transgenic
cells, indicating that the avidity of the interaction with the
TCRαβ cells was too low for detection (Figure 6E). The
TCRα chain transgenics with an elongated CDR3 had an
intermediate binding avidity. We demonstrated a func-
tional interaction between the tetramer and TCRαβ trans-
genic T cells by measuring cytokine production from
transgenic cells cultured in the presence of plate-bound
tetramer. In keeping with the Th2 phenotype, IL-4, IL-5,
IL-9 and IL-13 but not IFNγ were detected (Figure 6F).
The Th17 polarized T cell lines produced less IL-17 with
each successive re-stimulation such that by the fourth re-stimulation cytokine production was more in keeping with
that of a Th1 cell line (Figure 7A, B). We hypothesized
that this shift in cytokine production would be accompa-
nied by a reduction in tetramer binding avidity and longer
TCRVαCDR3 length as T cells with a IFNγ producing
phenotype clonally expand. In keeping with this, we ob-
served a reduction in tetramer binding avidity between
the first and fourth re-stimulations of polarized Th17 lines
such that at the fourth re-stimulation, tetramer binding
curves for Th1 and Th17 lines overlapped (Figure 7C, D).
TCR repertoire analysis at the first and fourth re-
stimulations confirmed that the change in cytokine pro-
duction and tetramer binding avidity occurred alongside
an increase in average TCRVαCDR3 length (Figure 7E).
The mean TCRVαCDR3 lengths for the first and fourth
re-stimulations are 10.95 + 0.22 (SE) (n = 37) and 11.39 +
0.21 (SE) (n = 51), respectively, (P = 0.038). The difference
in mean CDR3α length between the first and fourth re-
stimulation shows progression to a TCR repertoire with
longer CDR3α regions as cells lose their IL-17 producing
phenotype and become more Th1-like in their tetramer
binding characteristics and cytokine production.
In light of previous observations in TCR transgenics,
notably the early studies by Hosken and colleagues [41]
using the DO11.10 TCR transgenic line, it might be pre-
dicted that the Th2 TCR transgenic-skewed polarization
may be overcome by altering peptide dose. Certainly,
among the many factors that can skew cytokine bias
would be peptide dose itself. In the DO11.10 TCR trans-
genic studies, it was shown that under otherwise equiva-
lent in vitro primary culture of naïve cells, mid-range
peptide doses favored the generation of moderate IFNγ
responses, while either higher or lower doses favored a
switch to development of more Th2-like responses, giving
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Figure 3 (See legend on next page.)
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Figure 3 The ex-vivo response of TCRα transgenic T cells show impaired IFNγ response and selection of a preferred TCRβ partner
chain. (A) TCRα chain transgenic and littermate controls were immunized with PLP 56 to 70/CFA on Day 0 and PLP 56 to 70/IFA on Day 28. T cell
proliferation is similar in the two groups. Data shown are mean values ± SE (TCRα transgenic (black bars), n = 4 mice at Day 10, 6 at Day 28 and 7 at
Day 32; littermate controls (white bars), n = 8 mice at Day 10, 8 at Day 28 and 9 at Day 32). The data are representative of three independently
performed experiments. (B) Immediately ex-vivo at Day 10, both groups make similar amounts of IFNγ, but at Day 28 no IFNγ response is seen in the
TCRα transgenics (*P <0.05; Mann-Whitney U test) or subsequently after re-challenge at Day 32, (C) TCRα transgenics show an impaired IFNγ response
compared to controls. (D) T cells from the TCRα chain transgenics were harvested at Day 32, cultured with peptide for 48 h and TCRβ chain CDR3
analysis of CD4+ CD69+ (n = 50 sequenced receptors from cDNA of bulk, sorted T cell lines) and CD4+ CD69− (n = 48 sequenced receptors from cDNA
of bulk, sorted T cell lines) cells carried out. The TCRα chain transgenic impaired IFNγ phenotype correlates with clonal expansion of a dominant TCRβ
chain (TRBV2, TRBJ2-5 CDR3 CASSQAGTGEDTQYF). (E) Spectratyping analysis of CD4+CD69+ TCRα chain transgenic and littermate control cells was
carried out using V gene specific primers.
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http://www.biomedcentral.com/1741-7007/12/32the IFNγ response curve the form of a bell-shaped curve
[41]. We, therefore, performed a set of experiments in our
system to examine the behavior of the Th2-derived trans-
genic TCR across a checker-board of low to high peptide
priming dose and a low to high in vitro re-stimulation
dose. Our previous experiments had typically utilized a
priming and re-stimulation dose of 25 μg/ml, correspond-
ing to 13 μM towards the upper-end of the concentration
range that had been tested by Hosken and colleagues using
naïve T cells in vitro. We initially primed Th2 TCRαβ
transgenic mice with peptide at 5, 25 or 125 μg (Figure 8).
Popliteal LNC were then challenged in vitro with a titrated
dose of peptide from 0.1 to 100 μg/ml. As we had seen be-
fore, peptide priming with 25 μg/ml did not trigger an ex-
vivo IFNγ response, though IFNγ could be elicited at either
a higher or lower dose of peptide priming, 5 or 125 μg/ml.
Thus, these findings are reminiscent of the studies by Hos-
ken and colleagues, except that the mid-range peak of
IFNγ production that had been seen by them for the
DO11.10 TCR is here exchanged, using a Th2 TCR, for a
low/high range peak of IFNγ production. Our curve is the
reciprocal of the DO11.10 finding. Furthermore, the mid-
range dose of priming with 25 μg/ml peptide was associ-
ated with increased transcription of both GATA-3 and
RORγT. Thus, while there is a constraint on IFNγ activa-
tion, this is peptide dose dependent and can be over-
ridden by either high or low dose peptide priming.
We then used this checker-board titration to analyze
cytokine secretion in T cell lines from peptide primed
Th2 TCRαβ transgenic mice, assaying their profile after
the third re-stimulation in vitro. The findings are sum-
marized in Figure 9. IL-4 responses are depicted in blue,
IL-13 in green and IFNγ in red. The key arbiter of cyto-
kine profile in vitro appeared to be the dose of peptide
used for in vitro re-stimulation of the lines. That is,
whether initial priming was with 25 or 125 μg, the
T cells lines produced relatively large amounts of IL-4
and IL-13 but little or no IFNγ when re-stimulated with
peptide in the range 0.1 to 10 μg/ml. However, irrespective
of the initial priming dose, the T cell lines showed an IFNγ
response when re-stimulated in vitro with 100 μg/ml
peptide.Figure 10 is a schematic summarizing the flow of ex-
periments designed here to test the hypothesis that elon-
gated TCR alpha chain complementarity-determining
region 3 favors a Th2-skewed CD4 phenotype.
Discussion
There has been considerable effort devoted to elucidat-
ing the structural biology of the TCR complex, with 10s
of structures solved, yet clear models for the way in
which the ligand/receptor interaction between pMHC
and TCR may give rise to the very diverse array of T cell
effector programs have been elusive [42,43].
Most TCR transgenic lines are generated without re-
gard for specific features of the cytokine profile of the
parental cell from which they were derived. Experiments
in some autoimmune models bear on this insofar as
there are examples in which T cell clones were impli-
cated in an autoimmune effector mechanism and the
TCR transgenics derived from them can mediate a spon-
taneous disease phenotype dependent on preferential
use of a similar cytokine profile [44]. Candon and col-
leagues generated transgenics for the TCR of a self-
reactive Th2 clone, showing that a proportion of the
mice spontaneously developed autoimmune gastritis
characterized by eosinophilic infiltration of the gastric
mucosa and Th2 differentiation of transgenic T cells in
the gastric lymph node [45]. Appropriate Th polarization
is most readily attributed to T cells engaging pMHC in
the context of an antigen presenting cell (APC) that has
been activated by innate signals to provide a particular,
polarizing environment [46]. Could another aspect of
the polarization reside in the TCR sequence itself? This
would have evolutionary value as a contributory me-
chanism in polarization since, without it, the appropri-
ateness, or otherwise, of the effector response could be
at the mercy of influence by any other concurrent pro-
cesses and/or infections. It is self-evident that there may
be TCR structures that are ‘vanilla’ in nature and capable
of being diverted readily to either a Th1 or Th2 pro-
gram; DO11.10 is the prototypic example [21]. Knowing
that TCRs of CD4 cells have been reported across a mo-
derately broad range of affinities and also that affinity/
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Figure 4 Re-stimulation in non-polarizing conditions of TCRα transgenic cultures in vitro shows progressive focusing of favored TCRβ
usage correlating with adoption of a Th2 cell phenotype. CFA/peptide primed draining lymph nodes were used to establish T cell lines
in vitro from TCRα transgenic lines 20 and 34 with an elongated Valpha CDR3 region, TCRα transgenic line 30 with a short Valpha CDR3 region,
and littermate controls. Every 10 days, lines were re-stimulated with peptide and APC. (A) Analysis of the TCRβ chain repertoire of TCRα chain
transgenic lines 20, 34 and littermate control T cell lines at successive re-stimulations. Sequence analysis of the repertoire of TCRβ CDR3 regions
for TCRα chain transgenic and littermate control T cell lines at the re-stimulation numbers shown. The percent of each T cell line TCRβ repertoire
attributed to each unique TCRβ chain sequence identified is shown. (B) cDNA from TCRα chain transgenic line 20 and littermate control T cell
lines at re-stimulation numbers 2, 4 and 6 was used to spectratype Vβ gene families TRBV2, TRBV13-1, TRBV16 and TRBV31. (C) IFNγ, IL-4, -5, -13
were measured at each re-stimulation of TCRα chain transgenic lines with an elongated CDR3 (line 20) (black bars) (n = 3), transgene negative
littermate control lines (white bars) (n = 5) and TCRα chain transgenic lines with a short CDR3 (line 30) (gray bars) (n = 3). (D) Relative expression
level of GATA-3 was determined by real-time PCR for TCRα chain transgenic lines with an elongated CDR3 (line 20) (black bars) (n = 3) compared
to littermate control lines (n = 5). Error bars indicate SE. This experiment was repeated on three separate occasions. APC, antigen presenting cell.
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http://www.biomedcentral.com/1741-7007/12/32avidity are key determinants of cytokine polarization, it
may be predicted that TCRs of different structures would,
all else being equal, show inherent bias to different effector
profiles. The principle that TCR sequence correlates with
function is accepted in the special case of the Treg versus
Teff TCR repertoires [47], although even in this setting,
phenotypic differences have proved difficult to define [48].
We show, using new TCR transgenic models, that an
elongated TCRα derived from a strongly Th2-skewed
T cell line retains imprinting of that effector program tothe extent that, even in the face of an overwhelming Th1-
polarizing environment, such as immunization in CFA
containing M. tuberculosis, T cells can proliferate while
lacking IFNγ responsiveness. While the polarization is
mediated through the selection of appropriate CDR3α re-
gions and the constraints on TCRβ selection are less ap-
parent, the full Th2 program is clearly dependent on
selecting the correct TCRαβ pair.
A starting point for the studies here was to reappraise
more broadly our earlier observations about preferential
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Figure 5 (See legend on next page.)
Reynolds et al. BMC Biology 2014, 12:32 Page 14 of 24
http://www.biomedcentral.com/1741-7007/12/32
(See figure on previous page.)
Figure 5 TCRVαβ transgene pair impacts on cytokine production and transcriptional profile. (A) TCRαβ transgenics or littermate controls
were primed with peptide in CFA and DLN cells harvested at Day 10. 3H-thymidine incorporation and cytokine production was determined from TCRαβ
transgenics (filled triangles; n = 6) and controls (filled squares; n = 10). Error bars indicate ± SE. This is representative of three separate experiments.
(B) TCRαβ transgenic cell lines (black bars) (n = 3) and littermate control lines (white bars) (n = 5) were established from primed DLN cells from mice
primed 10 days earlier with PLP56 to 70/CFA and re-stimulated every 10 days through to four cycles in the absence of any exogenous polarization.
(C) At each re-stimulation the relative expression of IFNγ, GATA-3 and RORγT was determined. Error bars indicate SE. (D) TCRαβ (filled triangles; n = 10),
TCRα chain transgenics (filled circles; n = 12), and littermate controls (filled squares; n = 27) were primed with peptide/IFA and at Day 10, DLN cells
were harvested and 3H-thymidine incorporation and cytokine production analyzed. These data are representative of three independently performed
experiments. CFA, Complete Freund’s adjuvant; DLN, draining lymph nodes.
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http://www.biomedcentral.com/1741-7007/12/32selection of the TCR repertoire. This can be thought of as
‘avidity-associated functional maturation’ of the response;
while it has long been known from many pMHC examples
that the TCR repertoire can focus in on sometimes highly
dominant receptor usage, we add the observation that this
choice is highly influenced by factors driving Th1/Th2
polarization. A key observation, reiterated in the current
study, had been that Th2 polarization is associated with
CDR3α chains with somewhat elongated loops. In the
present study, we have extended this analysis to investiga-
tion of Th17-polarized cultures. Once again, TCRβ chains
remained relatively heterogeneous while TCRα sequences
rapidly attain focused, preferential usage; although se-
lected out of the same starting pool, the Th17 receptor
usage is dissimilar to either Th1 or Th2 lines. Like Th1
lines, TCRα chains are invariably of the Th1-like, short,
CDR3α type. We found no examples of elongated CDR3α
chains in Th17 cells. This may be taken to mean that, like
Th1 cells, Th17 activation is dependent on ‘high-end’
affinity activation and depends on activation that is in-
compatible with low affinity TCR activation. This is in line
with the relatively easy plasticity from Th17 to Th1 line-
ages, although it is also known that there are differences
between activation signals for Th1 and Th17 activation,
such as dependence on PKCθ [49]. On the other hand, we
found little similarity between the actual CDR3α se-
quences selected in Th17 and Th1 cultures. To our know-
ledge this study constitutes the first report of preferential
TCR usage associated with the Th17 phenotype with the
associated implications for differential avidity of Th17
cells. Th17 cells are predicted to be at the upper end of
the avidity spectrum, with associated implications for dif-
ferential signaling and synapse formation.
A number of studies have sought to relate changes in
the TCR repertoire to the development of the T cell re-
sponse, although not in the specific context of cytokine
programs. Studies of CD8 responses have variously
shown either a stochastic relationship between the initial
response and the expanded repertoire, or substantial
focusing with preferential selection of particular clono-
types, sometimes associated with enhanced avidity [50].
Those examples of CD4 repertoire selection that havebeen investigated in detail have also tended to focus on
the progressive loss of low-affinity clones to achieve the
‘best fit’ [51,52]. What is unclear is how this model could
be reconciled with a continuing requirement for dif-
ferential avidities associated with alternate cytokine pro-
grams. Certainly, cells within a Th2 memory population
can make IFNγ if reactivated in the context of innate Th1
signals [53]. That is, it might not be possible to maintain
an overall dominance of Th2 clones in the face of a TCR
repertoire progressively shifting to higher avidity. For ex-
ample, in Th1/Th17 dependent experimental autoimmune
encephalomyelitis (EAE) TCR transgenic models, strength
of pMHC-TCR interaction is correlated with more aggres-
sive, spontaneous disease [54]. Conversely, decreased CD4
expression by polarized Th2 cells has been shown to con-
tribute to reduced TCR-induced phosphorylation and Ca2+
signaling [55].
Profiling of co-stimulatory molecules on Th1 and Th2
lines showed differences compatible with the notion of
enhanced avidity promoting Th1 differentiation. Up-
regulation of CD40L expression in Th1 cells is a pre-
viously well-documented example of this phenomenon,
confirmed here [14]. Up-regulation of ICOS was a strong
marker of Th2 differentiation, while CD5 up-regulation
was a strong marker of Th1 differentiation. In line with
the notion of CD5 up-regulation as a marker of enhanced
avidity in Th1 cells, CD5 expression in thymocyte selec-
tion is correlated with avidity/signal intensity of the posi-
tively selecting TCR-pMHC interaction [56].
For differential engagement between pMHC on the APC
and the TCR to lead to these very divergent transcription
programs, there must be substantive differences in signal-
ing, from initial formation of the immune synapse. A num-
ber of studies have previously considered differences in
immune synapse formation and TCR signaling between
Th1 and Th2 cells: most of these are compatible with the
notion that the synapse leading to Th2 differentiation
comprises a less tightly focused, lower avidity complex.
Th2, but not Th1 cells, fail to cluster TCR at the cell-
cell interface due to increased expression of cytotoxic
T-lymphocyte antigen 4 (CTLA-4) [57]. In line with this,
co-clustering of TCR with CD4 in lipid rafts is more
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Figure 6 (See legend on next page.)
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Figure 6 Th2 derived TCRαβ has low avidity. (A) ELISPOT assays for Th1 (open squares; n = 4), Th2 (open triangles; n = 3) and Th17 (open
diamonds; n = 6) polarized, non-transgenic cell lines cultured for eight days detect IFNγ, IL-4 and IL-17 producing cells, respectively, in response to
increasing concentration of PLP 56-70 peptide. (B) Th1 (open squares; n = 6), Th2 (open triangles; n = 6) or Th17 (open diamonds; n = 2) polarized,
non-transgenic cell lines incubated with H2-Ag7/PLP 56-70 or control (H2-Ag7/CLIP 103-117) tetramers on Day 8 after primed draining lymph nodes
(DLN) were incubated with peptide. Percentages shown are the difference between staining with H2-Ag7/PLP 56-70 and control (H2-Ag7/CLIP 103-117)
tetramers. Data are representative of three separate experiments. (C) Th1 and Th2 polarized cell lines (A, B) have similar levels of CD3
expression. (D) ELISPOT assays for unpolarized, Th2 cytokine producing TCRαβ lines (filled triangles; n = 3) and IFNγ producing littermate
control lines (filled squares; n = 5) cultured in the absence of polarizing cytokines through two successive 10-day cycles of re-stimulation
with peptide, detect IL-4 and IFN-γ producing cells, respectively, in response to increasing concentration of PLP 56-70 peptide. (E) Unpolarized Th2
cytokine producing TCRαβ lines (filled triangles; n = 6), TCRα lines (filled circles; n = 6) and IFNγ producing littermate control lines (filled
squares; n = 5) cultured through two successive 10-day cycles of re-stimulation with peptide, incubated with H2-Ag7/PLP 56-70 or control
(H2-Ag7/CLIP 103-117) tetramers at the concentrations shown. Percentages shown are the difference between staining with H2-Ag7/PLP
56-70 and control (H2-Ag7/CLIP 103-117) tetramers. (F) Functional binding of tetramers determined by cytokine production from unpolarized
TCRαβ lines and littermate controls following incubation with plate bound H2-Ag7/PLP 56-70 tetramer. Cytokine concentration shown is a
total minus background cytokine production for cells incubated with phosphate-buffered saline (PBS) only. The TCRαβ transgenic line (black
bars) does not make IFNγ while the littermate control line (white bars) does. An IFNγ absent cytokine profile is elicited from the TCRαβ
transgenic line.
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http://www.biomedcentral.com/1741-7007/12/32common in Th1 cells [58]. Th2 immune synapses are mor-
phologically distinct, characterized by the failure to ex-
clude CD45 and ICAM-1 from the central zone [59].
These changes are presumed to contribute to diminished
strength of signaling. Furthermore, a number of studies
have considered mechanisms by which these differ-
ences might in turn lead to qualitative signaling differ-
ences and alternate transcriptional choices. Strength of
signaling has been shown to affect the balance of
NFATp and NFATc binding activity, thus directly regu-
lating IL-4 transcription [60]. We predict from our
TCR analysis of Th1, Th2 and Th17 lines that Th17
synapse formation and signaling would be distinct from
the low avidity interactions characterizing Th2 activa-
tion and more reminiscent of Th1 activation.
Jameson and Masopust [61] have summarized a num-
ber of studies on the cost to the quality of memory of
too much stimulation with the term, ‘everything in
moderation: better memory by avoiding over-exertion.’
Is it possible that our Th2 TCRαβ transgenic model in
some way elicits a response that is sub-optimal through
excessive or inappropriate stimulation? While our ob-
servations here have focused largely on cytokine
polarization of the initial response, all of the markers
assessed here, including IL-2 activation, CD127 expres-
sion and anti-apoptotic markers indicate that responder
cells in this transgenic system are fully fit to respond,
they merely choose to do it in a different way.
The key evidence that cytokine program can be influ-
enced by the selected TCRαβ sequence itself came with
the observation that by transgenic expression of a Th2
derived receptor, we produced mice that are ‘Th1-
averse’, even in the face of the most powerful possible
stimulus to reverse this; despite showing strong prolif-
eration in response to peptide, as would be expected,
considerably higher than wild-type mice, there is noIFNγ or IL-17 response. Rather, the TCR transgenic
mice make a strong Th2 response, not seen at all in the
littermate controls. Why should this be the case? We
speculate that it is an evolutionary failsafe to ensure
pathogen-appropriateness of the response. In experimental
immunology, we tend to work with reductionist systems
where we can examine polarized Th1, Th2 or Th17 re-
sponses, unimpeded by other influences. However, in the
natural host response to infection there will be many com-
peting influences; thus, Th2 responses have presumably
evolved to provide protection against parasitic infestation,
yet in many parts of the world facing a major parasite
burden, there is also a high level of infection with M.
tuberculosis, itself providing a concomitant drive to Th1
and Th17 immunity [62]. Indeed, we have previously
described another clinical example of this type in respect
to the co-existence in the lung of sarcoidosis, which is
associated with strong Th1 responses, and Cryptococcus
neoformans, for which Th2 immunity is critical [63]. In
complex settings, being able to avoid potentially dangerous
reprogramming from pathogen-driven, cytokine milieu
and promoting an appropriate effector response, is vital.
Cells with lower affinity TCRs adopt a Th2 phenotype
when primed in the absence of competition from cells
with higher affinity receptors [64]. Evidence that the
Th2-derived TCR used in these studies are of low affin-
ity comes from molecular modeling studies done in
collaboration with Yvonne Jones’ laboratory [20]. In the
present study, we were able to confirm those predic-
tions using direct tetramer binding studies. We show
here that while WT littermate primed cells respond to
plate-bound tetramer by making IFNγ, TCRαβ Tg cells
respond by making Th2 cytokines, but no IFNγ. This
further emphasizes the fact that the property is purely
one of the interaction between pMHC and TCR, un-
influenced by other contributory differences of co-
A B
C
CDR3 region CDR3 length %
DSGTYF CAAEGNNRIF FGDG 9 20
DSALYY CALSDRGPNYNVLY FGSG 13 13
DSGTYL CAMERTDNYAQGLT FGLG 13 13
DSAIYF CAASRGNMGYKLT FGTG 12 10
DSAAYF CAVRTDNYAQGLT FGLG 12 6
DSGTYF CAAEANTDKVV FGTG 10 6
DSAMYF CAATPNNYAQGLT FGLG 12 4
DSGTYF CAAEGYANKMI FGLG 10 4
DSAVYY CALGEGTNAYKVI FGKG 12 2
DSAVYY CVLGEGNNAGAKLT FGGG 13 2
DSAIYF CAASRGNNNRIF FGDG 11 2
DSAVYF CAVSGNNNNAPR FGAG 11 2
 DSGTYL CAMERTDNYAQGLT FGLG 13 2
 DSGTYL CAMERNNNNRIF FGDG 11 2
DSAMYF CAASRGNTDKVV   FGTG 11 2
DSGTYF CAAANYNQGKLI FGQG 11 2
DSALYY CALSDRGPNYVLY FGSG 12 2
DSGTYL CAMERGNTRKLI  FGLG 11 2
DSGTYL CAMERTDNYAQGLT FGLG 13 2
DSGTYL CAMERGNTRKLI  FGLG 11 2
CDR3 region CDR3 length %
DSGTYF CAAEGNNRIF FGDG 9 16
DSGTYF CAAGGRGGADRLT FGKG 12 16
DSAIYF CAASRGNMGYKLT FGTG 12 8
DSAVYY CALGSNYKLT FGKG 9 8
DSAAYF CAVSAGTGGYKVV FGSG 12 8
DSGTYF CAAEHYNQGKLI FGQG 11 6
DSGTYF CAGHNYAQGLT FGLG 10 6
DSGTYF CAAERSGANTGKLT FGHG 13 6
DSGTYF CAAYNYAQGLT FGLG 10 2
GSGTYF CAADRNSGTYQR FGTG 11 2
DSAVYF CAVSARNNNRIF FGDG 11 2
DSAVYF CAVSGNNNNAPR FGAG 11 2
DSAVYF CAVINTNTGKLT FGDG 11 2
DSAVYF CAVSASSNTDKVV FGTG 12 2
DSAMYF CAATPNNYAQGLT FGLG 12 2
DSGTYF CAAEAAGANTGKLT FGHG 13 2
DSAAYF CAVGGANTGKLT FGHG 11 2
DSGTYF CAADRTGANTGKLT FGHG 13 2
DSGTYF CAAVSYSQGKLI FGQG 11 2
DSAMYF CAASNGNTGKLT FGDG 11 2
DSGTYF CAAGRYGNEKIT FGAG 11 2
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Figure 7 Th17 polarized T cell lines have shorter TCRVαCDR3 length and higher tetramer binding avidity than Th1 and Th2 polarized
cell lines. Highly polarized Th1 (n = 6), Th17 (n = 6) and Th2 (n = 6) T cell lines derived from the same peptide immunizations of NOD.E mice
were maintained in culture through four re-stimulations in vitro. Cells were analyzed for cytokine production and H2-Ag7/PLP 56-70 tetramer
binding avidity. At the first re-stimulation (Day 10), IL-17 production and high avidity tetramer binding by the Th17 cell lines are noted (A, C).
At the fourth re-stimulation (Day 40), IL-17 production and tetramer binding avidity of the Th17 cell lines have decreased (B, D) and the
cytokine profile and tetramer binding characteristics now resemble those of the Th1 cell lines. (E) The TCRVαCDR3 chain repertoire of Th17
cells at the first (left hand panel) and fourth (right hand panel) re-stimulations were analyzed. The frequency (%) of each unique TCR sequence
identified is shown. The mean TCRVαCDR3 lengths for the first and fourth re-stimulations are 10.95 ± 0.22 (SE) (n = 37) and 11.39 ± 0.21 (SE)
(n = 51), respectively. The difference in mean CDR3α length between the first and fourth re-stimulation is statistically significant (P = 0.038)
and shows progression to a TCR repertoire with longer CDR3α regions as cells lose their IL-17 producing phenotype and become more Th1
like in their tetramer binding characteristics and cytokine production.
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http://www.biomedcentral.com/1741-7007/12/32stimulatory molecules. However, despite the fact that
both cell populations can be activated by tetramers,
binding to the transgenic T cells is sufficiently low as to
be undetectable. The tetramer binding studies, taken in
conjunction with the preferential TCR selection de-
scribed by us in polarized lines, predict that the prefer-
ence for TCR avidity will be Th17 > Th1 > Th2.Conclusion
We propose an additional and previously undefined
mechanism for ensuring the cytokine appropriateness
of CD4 immunity. TCR preferentially selected under
Th2 conditions tended to use elongated CDR3α loops
and when expressed in transgenics, skewed responses
away from secretion of IFNγ, favoring Th2 cytokines.
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http://www.biomedcentral.com/1741-7007/12/32Focusing on the T cell repertoire in antigen specific
adaptive immunity can bring with it information not
just about pMHC specificity, but also about the quali-
tative nature of the appropriate cytokine response.
Methods
Ethics statement
The work described in this manuscript was covered by
a Home Office Project License and approved by the
Imperial College Ethical Review Process.
Mice
To generate mice expressing an anti-PLP56-70/H2-Ag7
TCRα chain with the elongated CDR3α region, rearranged
TRAV17J50 segments amplified from NOD.E genomic
DNA and cDNA derived from a Th2 NOD.E T cell line
against PLP56-70 and containing the CDR3 region (CALE-
GIASSSFSKLVF) were subcloned into pTalphaCass [65]
(Figure 2A). Mice expressing a Th1 NOD.E T cell line de-
rived anti-PLP56-70/H2-Ag7 TCRα chain (TRAV10/J58)
with a shorter CDR3 region (CAASREGTGSKLSF) were
also generated (Figure 2B). To generate mice expressing
the anti-PLP56-70/H2-Ag7 TCRβ chain that pairs with the
Th2 line-derived TCRα chain, rearranged TCRBV31J2-3
(CAWSLGGGAETLYF) segments amplified from NOD.E
genomic DNA were cloned into pTbetaCass (Figure 2C).
(C57BL/6xCBA) F2 oocytes were microinjected and TCR-
positive founders identified by PCR and Southern. Two
TCRα chain transgenic lines with elongated CDR3 regions
(called TCRAV17J50elongatedCDR3-line 20 and TCRAV
17J50elongatedCDR3-line 34) and one TCRα chain trans-
genic line with a short CDR3 region (called TRAV10
J58shortCDR3-line30) are described here. All transgenic
lines underwent at least five generations of backcrossing
to NOD.E mice [66]. One TCRβ chain transgenic line is
described here in detail, and termed the TCRBV31J2-3
line. The TCRβ transgenic line was crossed with the TCRα
transgenic line 20 to make a TCRαβ transgenic lineA
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Figure 8 Impact of different in vivo peptide priming doses on ex-vivo
hind footpad with 5 μg/ml (open bars), 25 μg/ml (gray bars) or 125 μg/ml (bl
cells were re-stimulated with peptide at 0.1, 1.0, 10 or 100 μg/ml as indicated
ELISA (A). RNA was prepared from primed DLN immediately ex-vivo for real-tiexpressing the elongated TCRαCDR3 and its partner
TCRβCDR3 backcrossed onto a NOD.E background.
Immunization and T cell proliferation assays
PLP56 to 70, DYEYLINVIHAFQYV, was used for priming
T cell responses and the substituted analog carrying lysine
for tyrosine at positions 57 and 59 for in vitro re-
stimulation of cells [67] (Biosynthesis Inc, Lewisville, Texas,
USA). The substituted analog is necessary for in vitro stud-
ies as the original sequence is poorly soluble and cytotoxic.
The altered peptide retains the ability when used in vivo to
trigger the expected EAE phenotype [67]. Mice were im-
munized with 25 μg peptide in CFA or IFA (Sigma-
Aldrich, Gillingham, Dorset, UK) in the footpad or flank.
At Day 10 (unless otherwise stated) draining lymph nodes
(DLN) and spleen were removed and cell suspensions were
prepared in HL-1 medium (Lonza, Basel, Switzerland).
Cells were cultured in triplicate in 96-well plates in the
presence of peptide for three days. [3H]Thymidine was
added 18 h before termination, and cultures were har-
vested (MACH III M Harvester 96) for beta scintillation
counting (Wallac 1450 Microbeta TRILUX).
T cell lines
T cell lines from immunized LNC and spleen were initially
set up in the presence of 25 μg/ml PLP peptide. To gene-
rate Th1 lines, cells were cultured in medium containing
IL-2 (10 IU/ml) (National Institutes of Health, Bethesda,
MD, USA), 10 ng/ml of IL-12 (R&D systems, USA) and
10 μg/ml anti-IL-4 (National Institutes of Health, USA).
To generate Th2 lines, cells were cultured in medium
containing IL-2 (10 IU/ml) (National Institutes of Health,
USA), 10 ng/ml of IL-4 (R&D systems, Minneapolis,
Minnesota, USA) and 10 μg/ml of anti-IFNγ (Life Tech-
nologies Ltd, Paisley, UK). For Th17 lines, cells were ini-
tially cultured in 10 μg/ml anti-IFNγ (Life Technologies
Ltd, Paisley, UK), 10 μg/ml anti-IL-4 (National Institutes of
Health, USA), 20 ng/ml IL-6 (R&D Systems, USA) andB
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Figure 9 Impact of different in vitro peptide restimulation
doses on cytokine program of T cell lines. Th2αβ TCR transgenic
mice were primed with either 25 μg or 125 μg PLP 56-70 peptide in
CFA and T cell lines were cultured from DLN cells for three cycles of
re-stimulation and expansion using the peptide re-stimulation doses
indicated. Triplet bars for each set of culture conditions are arranged in
the order IL-4 (blues), IL-13 (greens) and IFNγ (reds). The darker the
color, the greater the response for that cytokine. An unfilled (white) cell
indicates no detectable response for that cytokine. For IL-4: unfilled,
below detection limit; pale blue, response of <50 pg/ml; dark blue,
response of >50 pg/ml. For IL-13, unfilled, below detection limit; green,
response of <500 pg/ml; dark green, response of >500 pg/ml. For IFNγ
(assayed by qPCR), unfilled (white) indicates relative expression of 1;
pale pink indicates relative expression <25; dark pink indicates relative
expression between 25 and150; red indicates relative expression >150.
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http://www.biomedcentral.com/1741-7007/12/322 ng/ml TGFβ (R&D Systems, USA) and expanded in
medium containing 10 IU/ml IL-2 (National Institutes of
Health, USA) and 20 ng/ml IL-23 (R&D Systems, USA). Fol-
lowing the addition of cytokines, cultures were incubated
for an additional eight days. Cells were then resuspended
in RPMI 1640 medium (Invitrogen, Life Technologies,
UK) and 10% FCS, and re-stimulated with 25 to 50 μg/ml
peptide in the presence of irradiated, syngeneic spleno-
cytes. The 10-day cycle was repeated as required.
T cell cytokine assays
T cell proliferation assays of immunized lymph node cells
were set up as described above. After 66 h, 50 μl of super-
natant was removed from each well to determine cytokine
production. The IL-2, IL-4, IL-5, IL-9, IL-10, IL-13, IL-17
and IFNγ content was measured by ELISA (R&D Systems,
UK or BD Biosciences, Franklin Lakes, New Jersey, USA).
IFNγ (2BScientific Ltd, Upper Heyford, UK), IL-4 (BD
Biosciences, USA), IL-17 (R&D Systems, UK). ELISPOT
assays (R&D Systems, UK) were performed using 1.2 ×
104 T cells and 3 × 105 APCs per well with varying con-
centrations of peptide. Numbers of spots per well were de-
termined using an AID ELISPOT reader (Autoimmun
Diagnostika GmbH, Straßberg, Germany).
Cytokine storm induction
Mice were immunized intraperitoneally with 200 μg of
Staphylococcal Enterotoxin B (SEB) (Sigma Aldrich, UK)
or via the footpad with phosphate-buffered saline (PBS) or
50 μg of PLP peptide in CFA. Tail bleed samples
were collected prior to immunization and at 2, 24 and
72 hours post immunization. Serum from tail bleed sam-
ples was used to measure IFNγ and TNF-α by ELISA
(R&D Systems, UK). Thymocytes were harvested at seven
days post immunization. PE-anti-CD4 (clone GK1.5,
eBioscience, San Diego, California, USA) and fluorescein
isothiocyanate (FITC)-anti-CD8 (clone 53 to 6.7,
eBioscience, USA) were used to determine the CD4:CD8
ratio of thymocytes and to isolate CD4 single positive thy-
mocytes by cell sorting on a FACS Aria II (BD Biosciences,
USA).
Flow cytometry
Cell suspensions from Th1/Th2 cell lines at eight days
post-re-stimulation were labeled with optimal concentra-
tions of the following labeled monoclonals: PE-anti-CD4
(GK1.5), PE-anti-CD40L (MR1), PE-anti-ICOS (7E.17G9),
PE-Rat-IgG2b isotype control, FITC-anti-CD4 (GK1.5),
FITC-anti-CD69 (H1.2 F3), FITC-anti-CD3 (145-2C11),
FITC-anti-CD5 (53–7.3), FITC-anti-CD54 (YN1/1.7.4),
FITC-anti-CD127 (A7R34), FITC-Rat IgG2b isotype con-
trol; all from eBioscience; FITC-anti-OX40 (OX-86)
from Serotec, UK; APC-anti-CD62L (MEL-14) (Immu-
noTools, Friesoythe, Germany); and V500-anti-CD4(RM4-5) (BD Biosciences, USA). Data were collected on
FACSCalibur (BD Biosciences, USA) and analyzed with
CellQuest software (BD Biosciences, USA) and FlowJo
software (Tree Star, Inc., Ashland, Oregon, USA).TCR spectratyping
Repertoire analyses were performed using a protocol
modified from Pannetier et al. [68]. Total RNA was
isolated from cell suspensions (Stratagene, Santa Clara,
California, USA) followed by cDNA synthesis using
SuperScript III (Invitrogen, Life Technologies). For each
cDNA, PCR reactions were performed using Vβ primers
(Milner et al., [64]) and a common 6-carboxyflurorescein-
amino-hexy (6-FAM) Cβ primer (6FAM-CTTGGGTGGA
GTCACATTTCTC). The PCR products were analyzed on
an ABI 3100 Prism Genetic Analyzer (Life Technologies,
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Figure 10 Schematic illustrating the flow of experiments used here to test the hypothesis that elongated TCR alpha chain
complementarity-determining region 3 favors a Th2-skewed CD4 phenotype.
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http://www.biomedcentral.com/1741-7007/12/32USA) using Gene Mapper ID Software version 3.2 (Life
Technologies, USA).
TCR subcloning and sequencing
TCRα and TCRβ transcripts were amplified from cDNA
prepared from bulk T cell lines (as described in the text)
by nested PCR as described [69] and ligated into the
pCR2.1 TA cloning vector, following transformation into
E. coli, individual colonies were sequenced using M13
primers (Cambridge Biosciences, Cambridge, UK) by di-
rect sequencing of purified PCR products. This was
carried out using the Big Dye Terminator v1.1 Cycle
Sequencing Kit and sequences, analyzed on an Applied
Biosystems 3130x1 DNA Analyzer. TCR sequences and
CDR3 region lengths were identified according to
the International Immunogenetics Information System
(IMGT) [70].
Antigen specific repertoire analysis
Single cells with a CD4+CD69+ phenotype were sorted
for repertoire analysis with a BD FACS Aria II and BD
FACSDiva software (BD Biosciences, USA) and RNA ex-
tracted from the sorted populations.
Class II tetramer binding
Tetramer binding was performed in RPMI/FCS and the
appropriate concentration of tetramer. H2-Ag7 tetramers
loaded with PLP56-70 or irrelevant, CLIP103-117 pep-
tide (PVSKMRMATPLLMQA) were used (provided by
the NIH Tetramer Facility, Emory University, Atlanta,
GA, USA). Cells were incubated with tetramer for 3 h
at 37°C before staining with FITC-anti-CD4 (GK1.5,
eBioscience, USA) and analyzing by FACS. For expe-
riments with naïve T cells, CD4+ T cells were isolated
from whole splenocyte cell suspensions by labelling with
CD4 (L3T4) Microbeads (Miltenyi Biotec, Bergisch
Gladbach, Germany) and positively selecting through an
autoMACS™ Separator (Miltenyi Biotec, Germany). For
plate-bound tetramer assays, wells of high-binding plates
(Corning, Corning, New York, USA) were incubated
with 10 μg/ml tetramer overnight. Wells were blocked
with 200 μl medium for 1 h at 37°C. A total of 5 × 104 T
cells/well and 1 μg/ml of soluble anti-CD28 (clone
37.51, eBioscience, USA) were incubated for 48 h and
supernatant collected for ELISA.
Real-time PCR analysis
RNA samples were prepared using Absolutely RNA® Micro-
prep or Nanoprep spin columns (Stratagene, USA) and
cDNA synthesized from 500 ng RNA using SuperScript III
reverse transcriptase (Invitrogen, Life Technologies, UK).
Real-time PCR reactions were run in triplicate and CT
values obtained using a MX3000P real-time PCR machine
(Stratagene, USA). Variance in the amount of RNAbetween samples was controlled for by normalizing to
18S. Because of differences in amplification efficiencies
between primer sets, relative levels of gene expression bet-
ween samples were calculated by using efficiency curves
to convert CT values to numerical values before norma-
lizing each gene of interest value with respect to the 18S
value for the same sample. The sample with the lowest
level of gene expression was assigned a value of 1. Levels
of gene expression in all other samples were expressed as
a value relative to 1. Gata3, Tbet, IFNγ, Bcl-xl, GAPDH
and 18S PCR primers, TaqMan MGB probes (FAM dye
labeled), as well as TaqMan Universal PCR Master Mix,
were purchased from Applied Biosystems (Applied Bio-
systems-Assays-on-Demand Gene Expression Assay) and
RORγt primers were purchased from Sigma-Aldrich (sense
primer:5′ GTCTGCAAGTCCTTCCGAGAG, antisense
primer:5′ ATCTCCCACATTGACTTCCTCTG, FAM
labeled probe:5′ [6FAM]CTGCGACTGGAGGACCTTCT
ACGGC[TAM]).Additional files
Additional file 1: Intracellular cytokine staining for antigen specific
T cell lines. A representative example of intracellular cytokine staining
for antigen specific T cell lines grown in (A) Th1 (n = 6) and (B) Th17
(n = 6) culture media. Cell lines were grown through one re-stimulation
in polarizing cell culture medium before intracellular cytokine staining
with FITC-conjugated IL-17 and PE-conjugated IFNγ antibodies. Note
that IFNγ producing cells readily differentiate within Th17 cultures,
notwithstanding clear-cut overall differences in preferential TCR usage
(Tables 1 and 3) and binding avidity (Figures 6 and 7).
Additional file 2: No bias in the TCR β chain repertoire of naïve
TCRVα chain transgenics at baseline or in a primary response in a
DLN at Day 10 post-immunization as demonstrated by spectratype
analysis. TCR β chain repertoire by spectratype analysis of (A) naïve
TCRα transgenic and littermate control splenocytes and (B) primed DLNs
at Day 10 post immunization with PLP 56 to 70 in CFA. V region specific
primers were used in combination with a FAM labeled constant region
primer to amplify TCRβ chain sequences from T cell cDNA templates.
Data shown are representative of experiments carried out with 10 TCRα
transgenic and 10 littermate controls and three independently performed
experiments.
Additional file 3: No difference in T-bet transcription between
TCRαβ transgenic and littermate control cell lines. TCRαβ transgenic
cell lines (black bars) (n = 3) and littermate control lines (white bars)
(n = 5) were established from primed DLN cells from mice primed
10 days earlier with PLP56 to 70/CFA and re-stimulated every 10 days
through to four cycles in the absence of exogenous polarization. At each
re-stimulation the relative expression of T-bet was determined. Error bars
indicate SE.
Additional file 4: Figure S5. TCRαβ transgenics show strong
functional T cell activation and absence of an enhanced apoptotic
program. TCRVαβ transgenic (n = 4) and littermate control (n = 5) mice
were primed with PLP56 to 70 on Day 0 (footpad, CFA) and Day 28
(flank, IFA). DLN and splenocytes were harvested at Day 10, Day 28 and
Day 32. At the Day 32, CD4+ T cells were analyzed for expression of
(A) the pro-survival factor Bclxl by real time PCR (Day 32) and (B) CD127
(Day 28), and (C) CD62L (Day 28) by flow cytometry. Statistical significance
between groups was determined using an unpaired t test. Error bars
indicate SE.
Additional file 5: Peptide priming of TCRVα, TCRVαβ transgenics or
littermate controls does not result in a systemic cytokine storm or
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http://www.biomedcentral.com/1741-7007/12/32reduced thymocyte numbers. (A) Littermate controls, TCRVα and
TCRVαβ transgencis were immunized with 200 μg SEB (striped bars)
(littermate controls, n = 5; TCRVα, n = 9; TCRVαβ, n = 9), PBS/CFA (white
bars) (littermate controls, n = 4; TCRVα, n = 4; TCRVαβ, n = 4), or 50 μg
PLP/CFA (black bars) (littermate controls, n = 4; TCRVα, n = 4; TCRVαβ,
n = 4). (B) Serum samples were collected at time points 0, 2, 24 and
72 hours from mice injected with SEB (striped bars), PBS/CFA (white bars) or
50 μg PLP/CFA (black bars) and IFNγ (top row) and TNF-α (middle row)
levels measured by ELISA. On Day 7, total thymocyte counts and CD4/CD8
thymocyte ratios were determined (bottom row). CD4 single positive
thymocytes were isolated by cell sorting and the CDR3β repertoire of
(C) littermate controls and (D) TCRVα transgenic mice immunized with
PLP/CFA determined by TCR subcloning and sequencing.
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